Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2024-03-01 DOI:10.1097/WNF.0000000000000584

Ting Wang, Yimo Feng

{"title":"Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data.","authors":"Ting Wang, Yimo Feng","doi":"10.1097/WNF.0000000000000584","DOIUrl":null,"url":null,"abstract":"Objectives: Lasmiditan holds important potential in treating migraine, but its ideal dose remains elusive. This meta-analysis is conducted based on aggregate data and aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for acute treatment of migraine attack.Methods: PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were systematically searched, and we included the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model or fixed-effect model based on the heterogeneity. The primary outcome was pain free at 2 hours. Secondary outcomes included pain relief at 2 hours, pain free at 24 hours, most bothersome symptom free at 2 hours, and adverse events.Results: Seven randomized controlled trials and 6515 patients were included in this meta-analysis. Compared with lasmiditan 100 mg for migraine patients, lasmiditan 200 mg was able to significantly improve pain free at 2 hours (odd ratio [OR], 1.28; 95% confidence interval [CI], 1.14-1.44; P < 0.0001) and pain free at 24 hours (OR, 1.35; 95% CI, 1.14-1.60; P = 0.0005), but showed no effect on pain relief at 2 hours (OR, 1.00; 95% CI, 0.90-1.12; P = 0.98) or most bothersome symptom free at 2 hours (OR, 0.93; 95% CI, 0.83-1.03; P = 0.17). Lasmiditan 200 mg was associated with the increase in adverse events compared with lasmiditan 100 mg (OR, 1.28; 95% CI, 1.15-1.43; P < 0.0001).Conclusions: Lasmiditan 200 mg is more effective to improve pain free at 2 hours and 24 hours than lasmiditan 100 mg for the acute treatment of migraine patients.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 2","pages":"44-47"},"PeriodicalIF":0.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000584","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Lasmiditan holds important potential in treating migraine, but its ideal dose remains elusive. This meta-analysis is conducted based on aggregate data and aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for acute treatment of migraine attack.

Methods: PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were systematically searched, and we included the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model or fixed-effect model based on the heterogeneity. The primary outcome was pain free at 2 hours. Secondary outcomes included pain relief at 2 hours, pain free at 24 hours, most bothersome symptom free at 2 hours, and adverse events.

Results: Seven randomized controlled trials and 6515 patients were included in this meta-analysis. Compared with lasmiditan 100 mg for migraine patients, lasmiditan 200 mg was able to significantly improve pain free at 2 hours (odd ratio [OR], 1.28; 95% confidence interval [CI], 1.14-1.44; P < 0.0001) and pain free at 24 hours (OR, 1.35; 95% CI, 1.14-1.60; P = 0.0005), but showed no effect on pain relief at 2 hours (OR, 1.00; 95% CI, 0.90-1.12; P = 0.98) or most bothersome symptom free at 2 hours (OR, 0.93; 95% CI, 0.83-1.03; P = 0.17). Lasmiditan 200 mg was associated with the increase in adverse events compared with lasmiditan 100 mg (OR, 1.28; 95% CI, 1.15-1.43; P < 0.0001).

Conclusions: Lasmiditan 200 mg is more effective to improve pain free at 2 hours and 24 hours than lasmiditan 100 mg for the acute treatment of migraine patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Lasmiditan 200 毫克与 100 毫克治疗偏头痛的对比研究：基于综合数据的 Meta 分析。

目的：拉斯米坦在治疗偏头痛方面具有重要潜力，但其理想剂量仍难以确定。本荟萃分析基于综合数据，旨在比较拉斯米丹 200 毫克与 100 毫克治疗偏头痛急性发作的疗效：我们系统地检索了PubMed、Embase、Web of Science、EBSCO和Cochrane Library数据库，并纳入了比较拉斯米坦200毫克和100毫克对偏头痛患者疗效的随机对照试验。本荟萃分析根据异质性采用随机效应模型或固定效应模型。主要结果是 2 小时内无疼痛。次要结果包括 2 小时内疼痛缓解、24 小时内无疼痛、2 小时内无最令人烦恼的症状以及不良事件：本次荟萃分析共纳入了 7 项随机对照试验和 6515 名患者。与拉斯米坦100毫克治疗偏头痛相比，拉斯米坦200毫克能显著改善偏头痛患者2小时内的无痛症状（奇数比[OR]，1.28；95%置信区间[CI]，1.14-1.44；P < 0.0001）和24小时内的无痛症状（OR，1.35；95% CI，1.14-1.60；P = 0.0005），但对 2 小时疼痛缓解（OR，1.00；95% CI，0.90-1.12；P = 0.98）或 2 小时无最令人烦恼的症状（OR，0.93；95% CI，0.83-1.03；P = 0.17）没有影响。与拉斯米迪坦 100 毫克相比，拉斯米迪坦 200 毫克与不良事件增加有关（OR，1.28；95% CI，1.15-1.43；P <0.0001）：在偏头痛患者的急性期治疗中，拉斯米迪坦200毫克比拉斯米迪坦100毫克更能有效改善2小时和24小时的无痛状态。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.